Novelis' Forward-Looking IVUS technology platform expected to enable Volcano to offer an expanded line of minimally invasive diagnostic and
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a provider of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it has acquired Novelis, Inc., a privately-held company with proprietary ultrasonic visualization and therapy technology for minimally invasive diagnostic and therapeutic devices.
Novelis' proprietary Forward-Looking IVUS technology platform is expected to build upon Volcano's existing suite of products and further enhance Volcano's position as an imaging technology leader in the field of interventional medicine by enabling forward-looking IVUS and associated therapies in the interventional cardiology market. Volcano expects to add the Novelis products and capability onto its s5i multi-modality integrated platform/hub.
Novelis' core product line is based on Forward-Looking Intravascular
Ultrasound (FLIVUS) technology. The product line includes an image-guided
crossing catheter that combines visualization, steerability and RF tissue
ablation, which is designed to permit Interventional Cardiologists to
safely cross chronic total occlusions ("CTO") in the coronary and
peripheral arteries, and a forward-looking IVUS catheter (imaging-only
version) to facilitate current guidewire-based CTO crossing techniques as
well as other potential product offerings with possible applications
outside of vascular medicine. This platform tech
|SOURCE Volcano Corporation|
Copyright©2008 PR Newswire.
All rights reserved